Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity

Journal of General Virology

Volumn 91, Issue 5, 2010, Pages 1194-1206

  Yusim, Karina ^a   Fischer, William ^a   Yoon, Hyejin ^a   Thurmond, James ^a   Fenimore, Paul W ^a   Lauer, Georg ^b   Korber, Bette ^a   Kuiken, Carla ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS C VACCINE; MOSAIC VACCINE; MOSAIC VIRUS PROTEIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; POLYPROTEIN; PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; CONSENSUS; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG EFFICACY; GENE SEQUENCE; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOSAIC VIRUS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EPITOPES, T-LYMPHOCYTE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951030492     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.017491-0     Document Type: Article

References (54)

1. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G.M., Gao, F., Moyer, L. A., Kaslow, R. A. & Margolis, H. S. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341, 556-562. (Pubitemid 29384163)
2. Armstrong, G. L., Alter, M. J., McQuillan, G. M. & Margolis, H. S. (2000). The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31, 777-782.
3. Barouch, D.,O'Brien, K., Simmons, N., King, S., Abbink, P., Maxfield, L., Sun, Y. H., La Porte, A., Riggs, A. & other authors (2010). Mosaic HIV-1 antigens expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16, 319-323.
4. Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L. & other authors (2006). Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194, 1638-1649.
5. Cerny, A. & Chisari, F. V. (1999). Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30, 595-601. (Pubitemid 29409400)
6. Conry-Cantilena, C., VanRaden, M., Gibble, J., Melpolder, J., Shakil, A. O., Viladomiu, L., Cheung, L., DiBisceglie, A., Hoofnagle, J. & other authors (1996). Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334, 1691-1696.
7. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P. & Walker, C. M. (1999). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439-449. (Pubitemid 29205480)
8. Cucchiarini, M., Kammer, A. R., Grabscheid, B., Diepolder, H. M., Gerlach, T. J., Gruner, N., Santantonio, T., Reichen, J., Pape, G. R. & Cerny, A. (2000). Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203, 111-123.
9. Darling, J. M. & Wright, T. L. (2004). Immune responses in hepatitis C: is virus or host the problem? Curr Opin Infect Dis 17, 193-198.
10. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A. & other authors (1998). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339, 1493-1499.
11. Doria-Rose, N. A., Learn, G. H., Rodrigo, A. G., Nickle, D. C., Li, F., Mahalanabis, M., Hensel, M. T., McLaughlin, S., Edmonson, P. F. & other authors (2005). Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79, 11214-11224.
12. Erickson, A. L., Kimura, Y., Igarashi, S., Eichelberger, J., Houghton, M., Sidney, J., McKinney, D., Sette, A., Hughes, A. L. & Walker, C. M. (2001). The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883-895. (Pubitemid 34075370)
13. Farci, P. & Purcell, R. H. (2000). Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20, 103-126. (Pubitemid 30421412)
14. Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H. & other authors (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135-140.
15. Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C., Haynes, B., Letvin, N. L. & other authors (2007). Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13, 100-106. (Pubitemid 46067393)
16. Fischer, W., Liao, H. X., Haynes, B. F., Letvin, N. L. & Korber, B. (2008). Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLOS Comput Biol 4, e15. (Pubitemid 351230865)
17. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr, Haussinger, D., Diago, M., Carosi, G. & other authors (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
18. Gao, F., Weaver, E. A., Lu, Z., Li, Y., Liao, H. X., Ma, B., Alam, S. M., Scearce, R. M., Sutherland, L. L. & other authors (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79, 1154-1163.
19. Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H. & other authors (2002). Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
20. + T-cell response in acute hepatitis C. Gastroenterology 117, 933-941.
21. Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M. C., Ulsenheimer, A., Schraut, W. W., Schirren, C. A., Waechtler, M. & other authors (2003). Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125, 80-88. (Pubitemid 36799109)
22. + T cells with viral clearance in acute hepatitis C. J Infect Dis 181, 1528-1536.
23. + T cell responses during chronic hepatitis C virus infection. Clin Exp Immunol 131, 122-129.
24. Houghton, M. & Abrignani, S. (2005). Prospects for a vaccine against the hepatitis C virus. Nature 436, 961-966.
25. Inchauspe, G. & Michel, M. L. (2007). Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 14 (Suppl. 1), 97-103.
26. Inchauspe, G., Bach, G., Martin, P. & Bonnefoy, J. Y. (2009). Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol 28, 7-19.
27. Jutavijittum, P., Jiviriyawat, Y., Yousukh, A., Pantip, C., Maneekarn, N. & Toriyama, K. (2009). Genotypic distribution of hepatitis C virus in voluntary blood donors of northern Thailand. Southeast Asian J Trop Med Public Health 40, 471-479.
28. Kong, W. P., Wu, L., Wallstrom, T. C., Fischer, W., Yang, Z. Y., Ko, S. Y., Letvin, N. L., Haynes, B. F., Hahn, B. H. & other authors (2009). Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 83, 2201-2215.
29. Korber, B. T., MacInnes, K., Smith, R. F. & Myers, G. (1994). Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 68, 6730-6744. (Pubitemid 24294924)
30. Korber, B. T., Letvin, N. L. & Haynes, B. F. (2009). T cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 83, 8300-8314.
31. Lauer, G. M. & Walker, B. D. (2001). Hepatitis C virus infection. N Engl J Med 345, 41-52.
32. Lauer, G. M., Barnes, E., Lucas, M., Timm, J., Ouchi, K., Kim, A. Y., Day, C. L., Robbins, G. K., Casson, D. R. & other authors (2004). High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127, 924-936. (Pubitemid 39208424)
33. Lechner, F., Wong, D. K., Dunbar, P. R., Chapman, R., Chung, R. T., Dohrenwend, P., Robbins, G., Phillips, R., Klenerman, P. & Walker, B. D. (2000). Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191, 1499-1512. (Pubitemid 30257347)
34. Letourneau, S., Im, E. J., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L., Dong, T., Korber, B. & other authors (2007). Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2, e984. (Pubitemid 351472368)
35. Li, F., Malhotra, U., Gilbert, P. B., Hawkins, N. R., Duerr, A. C., McElrath, J. M., Corey, L. & Self, S. G. (2006). Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24, 6893-6904. (Pubitemid 46107181)
36. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965. (Pubitemid 32913521)
37. Mehta, S. H., Cox, A., Hoover, D. R., Wang, X. H., Mao, Q., Ray, S., Strathdee, S. A., Vlahov, D. & Thomas, D. L. (2002). Protection against persistence of hepatitis C. Lancet 359, 1478-1483.
38. Pawlotsky, J. M. (2003). The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis 16, 587-592.
39. Prince, A. M., Brotman, B., Lee, D. H., Pfahler, W., Tricoche, N., Andrus, L. & Shata, M. T. (2005). Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192, 1701-1709. (Pubitemid 41587819)
40. Rappuoli, R. (2001). Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19, 2688-2691.
41. Santra, S., Korber, B. T., Muldoon, M., Barouch, D. H., Nabel, G. J., Gao, F., Hahn, B. H., Haynes, B. F. & Letvin, N. L. (2008). A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 105, 10489-10494.
42. + T cell responses in monkeys that confer immune coverage of diverse HIV strains. Nat Med (in press).
43. Serruto, D., Serino, L., Masignani, V. & Pizza, M. (2009). Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 27, 3245-3250.
44. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197, 1645-1655.
45. Stoll-Keller, F., Barth, H., Fafi-Kremer, S., Zeisel, M. B. & Baumert, T. F. (2009). Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8, 333-345.
46. Swofford, D. L. (2003). PAUP*: phylogenetic analysis using parsimony (*and other methods), version 4. Sunderland, MA: Sinauer Associates.
47. Thimme, R., Oldach, D., Chang, K. M., Steiger, C., Ray, S. C. & Chisari, F. V. (2001). Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395-1406. (Pubitemid 33081515)
48. Thurmond, J., Yoon, H., Kuiken, C., Yusim, K., Perkins, S., Theiler, J., Bhattacharya, T., Korber, B. & Fischer, W. (2008). Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24, 1639-1640. (Pubitemid 351966164)
49. Verma, V., Chakravarti, A. & Kar, P. (2008). Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect Dis 61, 408-414. (Pubitemid 351970643)
50. Ward, S., Lauer, G., Isba, R., Walker, B. & Klenerman, P. (2002). Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 128, 195-203.
51. Yusim, K., Kesmir, C., Gaschen, B., Addo, M. M., Altfeld, M., Brunak, S., Chigaev, A., Detours, V. & Korber, B. T. (2002). Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76, 8757-8768.
52. Yusim, K., Richardson, R., Tao, N., Dalwani, A., Agrawal, A., Szinger, J., Funkhouser, R., Korber, B. & Kuiken, C. (2005). Los Alamos hepatitis C immunology database. Appl Bioinformatics 4, 217-225.
53. Zeuzem, S. (2004). Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140, 370-381.
54. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E., O'Grady, J., Reichen, J., Diago, M. & other authors (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343, 1666-1672.